From GlobeNewswire: 2025-06-03 09:20:00

The global Circulating Tumor Cells market is projected to grow from USD 11.6 billion in 2023 to USD 36.8 billion by 2032, with a CAGR of 13.7%. The increasing cancer burden, preference for non-invasive diagnostics, and clinical value of CTCs are key drivers. Real-time insights into cancer progression and treatment response are provided by CTCs.

In the US, the market was valued at USD 3.23 billion in 2023 and is expected to reach USD 10.17 billion by 2032. Factors contributing to this growth include biopharmaceutical presence, research infrastructure, government initiatives, and more clinical trials using CTCs. Liquid biopsy techniques and single-cell analysis are driving market adoption.

The largest share of the market in 2023 came from kits and reagents, accounting for 44% of the total market share. CTC detection and enrichment methods held the largest share of CTC technologies market in 2023. Blood specimens accounted for over 72% of the industry, with research organizations and academia leading end-users in 2023.

North America led the global CTC market in 2023, with 37% contribution to the overall market. The Asia-Pacific region is expected to grow fastest due to increasing cancer patients, healthcare infrastructure progress, and diagnostic procedure improvements. Key players in the market include QIAGEN, Bio-Rad Laboratories, and Illumina, among others.



Read more at GlobeNewswire: Circulating Tumor Cells Market Size to Reach USD 36.8